8d agoThe FlyBULLISH 61Analyst
Archived explainer. For the current picture see today's CLYM page.
Why Is CLIMB BIO INC (CLYM) Stock Up Today?
By the Top Tier Newswire AI Desk · September 4, 2026 at 10:08 AM ET · reviewed against 15 wire stories
CLIMB BIO INC (CLYM) is up +6.24% in the latest session. Our newswire has captured 15 stories on CLYM across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Climb Bio Inc (CLYM) stock rose 6.24% to $15.50 in morning trading on Thursday as multiple analysts raised their price targets following encouraging Phase 1 trial data for its CLYM116 compound. The stock opened at $14.60 and reached a session high of $15.50 at 10:00 AM ET, with volume at 0.3 million shares, or 0.2 times the 3-month average.
What Happened
The stock’s upward move was driven by a series of analyst upgrades. B. Riley raised its price target to $30 from $26, BTIG increased its target to $32 from $20, and Baird raised its target to $25 from $21. Piper Sandler also raised its target to $40 from $23. These actions followed the release of Phase 1 data showing that a single 320 mg dose of CLYM116 suppressed APRIL by more than 90% and IgA by 60-75% for 12 weeks in healthy volunteers. The data has generated optimism about the drug’s potential in treating IgA nephropathy, with Phase 2 data expected in the first half of 2027.
What The Data Shows
The stock has traded between $1.54 and $18.33 over the past 52 weeks. It reached an 8-session high on September 4, printing 11 fresh 52-week highs and one 52-week low. The stock has a market cap of $864.4 million, a beta of 0.08, and an unprofitable earnings profile with a trailing twelve-month EPS of -0.83. Over the last eight sessions, the stock declined 9.3% from $16.40 to $14.87 before today’s rebound.
What To Watch
Investors should monitor the company’s Phase 2 IgA nephropathy data, expected in H1 2027, as well as continued analyst coverage. The stock’s recent volatility and analyst activity suggest ongoing interest in the company’s pipeline.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CLYM by the numbers
Last: $15.50Session: +6.24%7 sessions: -2.49%Coverage: 15 stories / 8 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $864M52w: $1.54 to $18.33
The headlines behind the move
9d agoInvesting.com Analyst RatingsBULLISH 61Analyst
BTIG raises Climb Bio stock price target to $32 on phase 1 data
BTIG raises Climb Bio stock price target to $32 on phase 1 data
9d agoThe FlyBULLISH 65Analyst
Climb Bio price target raised to $32 from $20 at BTIG
9d agoInvesting.com Analyst RatingsBULLISH 61Analyst
Baird raises Climb Bio stock price target to $25 on trial data
Baird raises Climb Bio stock price target to $25 on trial data
9d agoThe FlyBULLISH 61Analyst
Climb Bio price target raised to $25 from $21 at Baird
9d agoThe FlyBULLISH 61Analyst
Climb Bio price target raised to $40 from $23 at Piper Sandler
9d agoInvestorsHubBULLISH 68Product/PR
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
Climb Bio shares rose 17% after Phase 1 CLYM116 data showed more than 90% free APRIL suppression following a single 320 mg dose.
9d agoInvesting.com MarketsBEARISH 42General
Why is Climb Bio stock sliding today?
Why is Climb Bio stock sliding today?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on CLYM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CLYM move explainers: 2026-09-04 · 2026-09-03 · 2026-09-02